The book · Forthcoming
Pharmaceutical R&D AI, Data, and Digital
Strategy and Architecture
5 parts · 19 chapters · 350 figures
Why we wrote it
Advances in data, artificial intelligence, and digital technologies are transforming pharmaceutical R&D. Yet they are often discussed separately from the scientific and operational processes they are intended to support.
We wrote this book to bring these perspectives together. Understanding the role of technology in R&D requires understanding the work itself: how targets are discovered, molecules are developed, clinical trials are run, evidence is assembled for regulators, and the safety of medicines is monitored.
Our aim is to connect that scientific and operational context with the data, AI and digital architecture that enables it, providing a shared view for scientists, technologists, architects and leaders working across pharmaceutical R&D.
The framework
Every domain, through three lenses
Across the book, each R&D domain is examined the same way — so the science, the business processes and the architecture are read together, not in isolation.
-
01 Science
The biology, chemistry and scientific methods behind each domain.
-
02 Business Processes
How the work is actually carried out, end to end.
-
03 Architecture
The data, AI and digital systems that support it.
End to end
The pharmaceutical R&D journey
From the earliest biological target through development, approval and real-world patient safety — the whole value chain, in one book.
- Target Discovery
- Drug Discovery
- Pre-clinical
- CMC
- Clinical Trials
- Regulatory
- Patient Safety
Who it’s for
Across disciplines
For those shaping how medicines are discovered, developed and delivered across the pharmaceutical industry.
- Scientists
- Technologists
- Architects
- Leaders